<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990105</url>
  </required_header>
  <id_info>
    <org_study_id>FCS-2013-1</org_study_id>
    <secondary_id>R13044</secondary_id>
    <nct_id>NCT01990105</nct_id>
  </id_info>
  <brief_title>Treatment of Atrial Fibrillation in Finland</brief_title>
  <acronym>FinFib2</acronym>
  <official_title>Treatment of Atrial Fibrillation in Finland - the FinFib 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finnish Cardiac Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Finnish Cardiac Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FINFIB 2 is an observational investigator-driven study that seeks to examine current&#xD;
      treatment practice for atrial fibrillation in Finland. The investigators hypothesis is that&#xD;
      the treatment of atrial fibrillation has improved since the introduction of new&#xD;
      antiarrhythmic drugs and anticoagulants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FINFIB 2 is an observational investigator-driven study that seeks to examine current&#xD;
      treatment practice for atrial fibrillation (AF) in Finland. It will produce important&#xD;
      information such as whether the introduction of the new agents has taken place in accordance&#xD;
      with the treatment guidelines in different parts of Finland.&#xD;
&#xD;
      Working hypothesis is that the treatment of AF has improved since the introduction of new&#xD;
      antiarrhythmic drugs and anticoagulants. However, the investigators also expect to find out&#xD;
      that there are geographical differences in the use of these agents. The expect outcome is&#xD;
      that the investigators will identify these differences and be able to better homogenize the&#xD;
      treatment of AF in different parts of the country and different levels of the health care&#xD;
      system.&#xD;
&#xD;
      The study data will be obtained in the form of a cross-section sampling over two weeks. All&#xD;
      patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of&#xD;
      arrhythmia or other cardiac diseases during the study period will be included. The&#xD;
      investigators estimate the number of patients will be about 1000. Aside from background&#xD;
      information, risk data (e.g. CHA2DS2VASc), symptoms (EHRA classification), medication,&#xD;
      examinations and the choice of treatment, the only data recorded about each patient with AF&#xD;
      will be date of birth and gender. The patients will be divided into four groups according to&#xD;
      type of AF: 1. New onset AF, 2. Paroxysmal AF, 3. Persistent AF, 4. Permanent AF. The data&#xD;
      will be obtained by the local study doctor using online, protected data collection program.&#xD;
      The data will be stored on a secured server, which can be accessed for data entry by the&#xD;
      investigators at the study centers. The database is not a personal data register, as identity&#xD;
      codes will not be stored at any point and individual patients cannot be identified later&#xD;
      through the database. Only the investigator group will have the rights to use the database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to current atrial fibrillation treatment guidelines</measure>
    <time_frame>Data collected during the ER visit</time_frame>
    <description>All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included for assessment of the adherence of their treatment to current guidelines.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1013</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients with AF in the ER</arm_group_label>
    <description>All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study data will be obtained in the form of a cross-section sampling over two weeks. All&#xD;
        patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of&#xD;
        arrhythmia or other cardiac diseases during the study period will be included. The&#xD;
        estimated number of patients is about 1000.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All adult patients with ECG-diagnosed AF who attend emergency clinics for examination or&#xD;
        treatment of arrhythmia or other cardiac diseases during the study period will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pekka Raatikainen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Center Tampere Univerisity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juha Hartikainen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kuopio University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timo Lauri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mika Lehto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markku Mäkijärvi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juha Lund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heikki Mäkynen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Tampere University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <last_update_submitted>March 6, 2015</last_update_submitted>
  <last_update_submitted_qc>March 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>antiarrhythmic medication</keyword>
  <keyword>CHA2DS2VASc score</keyword>
  <keyword>HAS-BLED score</keyword>
  <keyword>CHADS2 score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

